Corcept Therapeutics is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...